sagopilone

has antineoplastic activity

Also Known As:

BAY-86-5302; DE-03757; EPO-477; SH-Y-03757; SH-Y03757A; ZK-219477; ZK-EPO; ZK-epothilone; 4,17-Dioxabicyclo(14.1.0)heptadecane-5,9-dione, 7,11-dihydroxy-8,8,12,16-tetramethyl-3-(2-methyl-5-benzothiazolyl)-10-(2-propen-1-yl)-, (1S,3S,7S,10R,11S,12S,16R)-

Networked: 34 relevant articles (11 outcomes, 23 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Hoffmann, Jens: 7 articles (04/2011 - 07/2008)
2.	Klar, Ulrich: 6 articles (04/2011 - 07/2008)
3.	Giurescu, M: 5 articles (08/2012 - 10/2009)
4.	Hammer, Stefanie: 4 articles (04/2011 - 07/2008)
5.	Schmelter, Thomas: 3 articles (06/2013 - 10/2010)
6.	Wiesinger, H: 3 articles (09/2011 - 10/2009)
7.	Eschenbrenner, Julia: 3 articles (04/2011 - 07/2008)
8.	Mittelstaedt, Kevin: 3 articles (04/2011 - 07/2008)
9.	Sommer, Anette: 3 articles (04/2011 - 03/2010)
10.	Winsel, Sebastian: 3 articles (04/2011 - 07/2008)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2012 - "Our study demonstrated clinically favorable safety, tolerability, and efficacy of sagopilone, which will help define the treatment of advanced tumors in more extensive clinical trials." 11/01/2011 - "Sagopilone treatment increased BMD In the mouse ovx model even though a non-optimized dose was used which is effective in tumor-bearing mice. " 12/01/2012 - "The purpose of this dose-escalation study was to investigate the safety, tolerability, and pharmacokinetics (PK) of sagopilone in refractory solid tumors. " 12/01/2009 - "In preclinical studies, sagopilone inhibited cell growth in a wide range of human cancer cell lines. " 10/20/2009 - "Twenty-three patients with malignancy resistant or refractory to standard treatment were enrolled into this study evaluating sagopilone doses from 0.6 to 7.0 mg m(-2). "
2.	Breast Neoplasms (Breast Cancer) 06/01/2009 - "Phase II clinical trials with sagopilone in patients with breast cancer are ongoing." 12/01/2011 - "Sagopilone was associated with modest CNS activity in patients with breast cancer; however median PFS was disappointing. " 01/01/2011 - "Here, we profiled sagopilone activity in breast cancer cell lines. " 01/01/2011 - "Evaluation of activity and combination strategies with the microtubule-targeting drug sagopilone in breast cancer cell lines." 12/01/2011 - "In this phase II study,we administered sagopilone to patients with breast cancer and brain metastases. "
3.	Ovarian Neoplasms (Ovarian Cancer) 11/01/2011 - "This open-label randomised phase II study investigated two infusion schedules of sagopilone in women with ovarian cancer. " 11/01/2011 - "Sagopilone is effective, with balanced tolerability, in patients with recurrent platinum-resistant ovarian cancer." 11/01/2011 - "Women with ovarian cancer recurring within 6 months of end of last platinum-containing treatment received sagopilone 16 mg/m(2) as a 3- or 0.5-h i.v. infusion every 21 days for up to 6 weeks. " 01/03/2012 - "This phase I/II, prospective, open-label trial investigated the efficacy and safety of sagopilone plus carboplatin in patients with recurrent platinum-sensitive ovarian cancer (OC). " 12/01/2009 - "Initial reports revealed that sagopilone was clinically active in advanced ovarian cancer, advanced melanoma and metastatic chemotherapy-naïve castration-resistant prostate cancer. "
4.	Brain Neoplasms (Brain Tumor) 12/01/2011 - "In this phase II study,we administered sagopilone to patients with breast cancer and brain metastases. " 04/01/2009 - "Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases." 12/01/2011 - "We conducted a phase II study of sagopilone, an epothilone B analogue that crosses the blood-brain barrier, in patients with breast cancer brain metastases. " 12/01/2011 - "A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases." 04/01/2009 - "Sagopilone demonstrated significant antitumor activity in orthotopic models of both glioblastoma and CNS metastases compared with paclitaxel or temozolomide, underlining the value of further research evaluating sagopilone in the treatment of brain tumors. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/01/2010 - "A comparison with response rates for established drugs showed the strong efficacy of Sagopilone in non-small cell lung cancer. " 06/01/2013 - "This multicenter, randomized, open-label, phase II study examined the efficacy and safety of three regimens with two doses and two infusion durations of second-line sagopilone in pretreated patients with stage IIIB or IV non-small-cell lung cancer. " 04/29/2011 - "Sagopilone inhibited proliferation of non-small cell lung cancer cell lines at lower nanomolar concentration. " 04/29/2011 - "We analyzed the differential mechanism of action of sagopilone in non-small cell lung cancer cell lines in vitro. " 06/01/2013 - "Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer."

Related Drugs and Biologics

1.	Epothilones (Epothilone)
2.	sagopilone
3.	epothilone B (EPO906)
4.	desoxyepothilone B (epothilone D)
5.	Platinum
6.	Antineoplastic Agents (Antineoplastics)
7.	Acetylcarnitine (Alcar)
8.	Paclitaxel (Taxol)
9.	Excipients (Suspending Agents)
10.	KOS-1584

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Castration
4.	Ovariectomy (Oophorectomy)